0001562180-22-007125.txt : 20221007
0001562180-22-007125.hdr.sgml : 20221007
20221007160522
ACCESSION NUMBER: 0001562180-22-007125
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221006
FILED AS OF DATE: 20221007
DATE AS OF CHANGE: 20221007
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Katkin Keith
CENTRAL INDEX KEY: 0001314596
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37708
FILM NUMBER: 221300802
MAIL ADDRESS:
STREET 1: C/O UROVANT SCIENCES, INC.
STREET 2: 5281 CALIFORNIA AVENUE, SUITE 100
CITY: IRVINE
STATE: CA
ZIP: 92617
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001395937
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320162505
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-419-1400
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-10-06
false
0001395937
Syndax Pharmaceuticals Inc
SNDX
0001314596
Katkin Keith
C/O SYNDAX PHARMACEUTICALS, INC.
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3
WALTHAM
MA
02451
true
false
false
false
Common Stock
2022-10-06
2022-10-06
4
M
false
20782.00
7.88
A
52782.00
D
Common Stock
2022-10-06
2022-10-06
4
S
false
20782.00
25.9009
D
32000.00
D
Common Stock
2022-10-06
2022-10-06
4
M
false
9117.00
8.93
A
41117.00
D
Common Stock
2022-10-06
2022-10-06
4
S
false
9117.00
25.9009
D
32000.00
D
Stock Options (Right to buy)
8.93
2022-10-06
4
M
false
9117.00
0.00
D
2028-05-23
Common Stock
9117.00
0.00
D
Stock Options (Right to buy)
7.88
2022-10-06
4
M
false
20782.00
0.00
D
2029-06-10
Common Stock
20782.00
0.00
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 73,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
The sale prices ranged from $25.0000 to $26.4600.
This option is fully vested.
/s/ Michael A. Metzger, as Attorney-in-Fact
2022-10-07